Source	PAID	Summary	Gene	Drug	GeneID	DrugID	Alternate	Dosing
DPWG	PA166184613	Select an alternative drug or reduce the initial dose of mercaptopurine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.	NUDT15	mercaptopurine	13756	1994	0	0
DPWG	PA166104989	The Dutch Pharmacogenetics Working Group Guideline for atomoxetine states for CYP2D6 ultrarapid metabolizers, to be alert to reduced efficacy of atomoxetine or select an alternative drug as a precaution.  Be alert to ADEs in CYP2D6 poor metabolizers.	CYP2D6	atomoxetine	4352	413	0	0
CPIC	PA166122686	The CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50%. Patients with the c.[2846A>T];[2846A>T] genotype may require a >50% dose reduction.	DPYD	fluorouracil	5039	1390	0	0
SEFF	PA166254881	Testing for certain DPYD variants in patients who are candidates for fluoropyrimidine treatment is recommended. The guideline contraindicates fluoropyrimidines in DPYD poor metabolizers, while DYPD intermediate metabolizers should have a 50% reduction in starting dose.	DPYD	capecitabine	5039	655	0	0
SEFF	PA166254881	Testing for certain DPYD variants in patients who are candidates for fluoropyrimidine treatment is recommended. The guideline contraindicates fluoropyrimidines in DPYD poor metabolizers, while DYPD intermediate metabolizers should have a 50% reduction in starting dose.	DPYD	fluorouracil	5039	1390	0	0
SEFF	PA166254881	Testing for certain DPYD variants in patients who are candidates for fluoropyrimidine treatment is recommended. The guideline contraindicates fluoropyrimidines in DPYD poor metabolizers, while DYPD intermediate metabolizers should have a 50% reduction in starting dose.	DPYD	tegafur	5039	3158	0	0
CPIC	PA166262321	Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines for patients who are SLCO1B1 or ABCG2 poor function phenotype. If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy). Patients with both ABCG2 poor function and SLCO1B1 poor/decreased function should be prescribed ≤10mg as a starting dose.	ABCG2	rosuvastatin	83	2890	1	1
CPIC	PA166262321	Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines for patients who are SLCO1B1 or ABCG2 poor function phenotype. If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy). Patients with both ABCG2 poor function and SLCO1B1 poor/decreased function should be prescribed ≤10mg as a starting dose.	SLCO1B1	rosuvastatin	19487	2890	1	1
DPWG	PA166104991	Avoid abacavir for patients who have the HLA-B*57:01 allele (patients who are "HLA-B*57:01-positive").	HLA-B	abacavir	8015	26	0	0
CPIC	PA166114461	Ivacaftor treatment is recommended only in cystic fibrosis (CF) patients that are either homozygous or heterozygous for certain CFTR variants.  See full guideline for disclaimers, further details and supporting evidence.	CFTR	ivacaftor	3250	1759	0	0
DPWG	PA166222801	The Dutch Pharmacogenetics Working Group Guideline for flucytosine states that patients with a DPYD activity score of 0 should avoid flucytosine. Patients with a DPYD activity score of 1 or 1.5 should be alert to the occurrence of severe side effects and flucytosine should be stopped if severe side effects occur.	DPYD	flucytosine	5039	1373	0	0
DPWG	PA166104964	The Dutch Pharmacogenetics Working Group Guideline for clomipramine recommends dose changes and to monitor the effect and side effects and the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), and intermediate (IM) metabolizer or to avoid clomipramine in PM and ultrarapid (UM) metabolizer.	CYP2D6	clomipramine	4352	838	0	0
CPIC	PA166176623	The CPIC Dosing Guideline for oxcarbazepine recommends an alternative drug for oxcarbazepine-naive patients carrying at least one copy of HLA-B*15:02 due to the association of this allele with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).	HLA-B	oxcarbazepine	8015	2468	0	0
CPIC	PA166105002	Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline/nortriptyline and CYP2C19, CYP2D6 to other tricyclics including desipramine. The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers.	CYP2D6	desipramine	4352	1005	0	0
DPWG	PA166182819	Patients who are CYP2D6 intermediate metabolizers should be given no more than 80% of the standard maximum dose of pimozide while patients who are CYP2D6 poor metabolizers should be given no more than 50% of the standard maximum dose.	CYP2D6	pimozide	4352	2619	0	0
CPNDS	PA166159180	The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of RARG , SLC28A3 , and UGT1A6 when prescribing anthracyclines for pediatric cancer patients. They recommend that pharmacogenomic testing of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6 *4 (rs17863783) should be performed in all pediatric cancer patients who are treated with daunorubicin or doxorubicin because the association of those genetic variants with anthracycline associated cardiotoxicity (ACT).	RARG	daunorubicin	17111	984	0	0
CPNDS	PA166159180	The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of RARG , SLC28A3 , and UGT1A6 when prescribing anthracyclines for pediatric cancer patients. They recommend that pharmacogenomic testing of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6 *4 (rs17863783) should be performed in all pediatric cancer patients who are treated with daunorubicin or doxorubicin because the association of those genetic variants with anthracycline associated cardiotoxicity (ACT).	SLC28A3	daunorubicin	19269	984	0	0
CPNDS	PA166159180	The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of RARG , SLC28A3 , and UGT1A6 when prescribing anthracyclines for pediatric cancer patients. They recommend that pharmacogenomic testing of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6 *4 (rs17863783) should be performed in all pediatric cancer patients who are treated with daunorubicin or doxorubicin because the association of those genetic variants with anthracycline associated cardiotoxicity (ACT).	UGT1A6	daunorubicin	22978	984	0	0
CPNDS	PA166159180	The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of RARG , SLC28A3 , and UGT1A6 when prescribing anthracyclines for pediatric cancer patients. They recommend that pharmacogenomic testing of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6 *4 (rs17863783) should be performed in all pediatric cancer patients who are treated with daunorubicin or doxorubicin because the association of those genetic variants with anthracycline associated cardiotoxicity (ACT).	RARG	doxorubicin	17111	1127	0	0
CPNDS	PA166159180	The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of RARG , SLC28A3 , and UGT1A6 when prescribing anthracyclines for pediatric cancer patients. They recommend that pharmacogenomic testing of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6 *4 (rs17863783) should be performed in all pediatric cancer patients who are treated with daunorubicin or doxorubicin because the association of those genetic variants with anthracycline associated cardiotoxicity (ACT).	SLC28A3	doxorubicin	19269	1127	0	0
CPNDS	PA166159180	The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of RARG , SLC28A3 , and UGT1A6 when prescribing anthracyclines for pediatric cancer patients. They recommend that pharmacogenomic testing of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6 *4 (rs17863783) should be performed in all pediatric cancer patients who are treated with daunorubicin or doxorubicin because the association of those genetic variants with anthracycline associated cardiotoxicity (ACT).	UGT1A6	doxorubicin	22978	1127	0	0
CPIC	PA166104996	Alternate non-tramadol analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific dose of codeine is warranted for CYP2D6 normal and intermediate metabolizers.	CYP2D6	codeine	4352	854	0	0
DPWG	PA166182844	Choose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and consider any additional risk factors for statin-induced myopathy.  If an alternative is not an option for patients with the 521 TC genotype, avoid simvastatin doses exceeding 40 mg/day and advise the patient to contact their doctor in the event of muscle symptoms.	SLCO1B1	simvastatin	19487	2979	0	0
CPIC	PA166105000	Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including doxepin. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.	CYP2C19	doxepin	4349	1126	0	0
CPIC	PA166105000	Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including doxepin. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.	CYP2D6	doxepin	4352	1126	0	0
CPIC	PA166127638	The CPIC Dosing Guideline for the selective serotonin reuptake inhibitors citalopram and escitalopram recommends an alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 ultrarapid metabolizers. For CYP2C19 poor metabolizers, consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.	CYP2C19	citalopram	4349	819	0	0
CPIC	PA166127638	The CPIC Dosing Guideline for the selective serotonin reuptake inhibitors citalopram and escitalopram recommends an alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 ultrarapid metabolizers. For CYP2C19 poor metabolizers, consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.	CYP2C19	escitalopram	4349	1263	0	0
CPIC	PA166105001	Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including trimipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.	CYP2C19	trimipramine	4349	3339	0	0
CPIC	PA166105001	Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including trimipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.	CYP2D6	trimipramine	4352	3339	0	0
RNPGx	PA166202521	Testing for TPMT genotype and phenotype is recommended for patients who are receiving azathioprine as an immunosuppressant. A dose reduction should be considered for patients with intermediate TPMT activity, while a greater dose reduction or selection of an alternate drug should be considered for patients with low TPMT activity.	TPMT	azathioprine	22019	432	0	0
DPWG	PA166104970	The Pharmacogenetics Working Group Guideline for codeine includes individual recommendations for cough or pain for CYP2D6 poor, intermediate, and ultrarapid metabolizer. In addition, for ultrarapid metabolizer, higher or lower doses and additional risk factors are taken into consideration.	CYP2D6	codeine	4352	854	0	0
DPWG	PA166104944	Choose an alternative drug to tegafur for patients with DPYD Activity Score of 0. For patients with a DPYD Activity Score of 1 or 1.5, avoid tegafur or start with a low dose and adjust the initial dose based on toxicity and efficacy. Fluorouracil and capecitabine are not alternatives for tegafur, as these are also metabolized by DPD. The DPWG evaluated DPYD genotyping as "essential" and recommend DPYD testing prior to initiating fluoropyrimidines.	DPYD	tegafur	5039	3158	0	0
CPIC	PA166104949	The updated guideline for pharmacogenetics-guided warfarin dosing is published by the Clinical Pharmacogenetics Implementation Consortium.  The  recommendations for dosing are for adult and pediatric patients that are specific to continental ancestry, and are based on genotypes from CYP2C9, VKORC1, CYP4F2, and rs12777823.	CYP2C9	warfarin	4351	3480	0	0
CPIC	PA166104949	The updated guideline for pharmacogenetics-guided warfarin dosing is published by the Clinical Pharmacogenetics Implementation Consortium.  The  recommendations for dosing are for adult and pediatric patients that are specific to continental ancestry, and are based on genotypes from CYP2C9, VKORC1, CYP4F2, and rs12777823.	CYP4F2	warfarin	4376	3480	0	0
CPIC	PA166104949	The updated guideline for pharmacogenetics-guided warfarin dosing is published by the Clinical Pharmacogenetics Implementation Consortium.  The  recommendations for dosing are for adult and pediatric patients that are specific to continental ancestry, and are based on genotypes from CYP2C9, VKORC1, CYP4F2, and rs12777823.	VKORC1	warfarin	23312	3480	0	0
DPWG	PA166104962	Reduce the dose of propafenone by 70% for CYP2D6 poor metabolizers, and monitor propafenone plasma concentrations or use an alternative drug for CYP2D6 intermediate and ultrarapid metabolizers.	CYP2D6	propafenone	4352	2730	0	0
DPWG	PA166104972	CYP2D6 poor metabolizers should receive 30% of the standard dose of imipramine, CYP2D6 intermediate metabolizers should receive 70% of the standard dose, and CYP2D6 ultra-rapid metabolizers should receive 1.7 times the standard dose. Patients should be monitored for the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose.	CYP2D6	imipramine	4352	1648	0	0
CPIC	PA166105003	Allopurinol is contraindicated in individuals with the HLA-B*58:01 variant allele ("HLA-B*58:01-positive") due to significantly increased risk of allopurinol-induced SCAR.	HLA-B	allopurinol	8015	127	0	0
DPWG	PA166104952	Select an alternative drug or reduce the initial dose of mercaptopurine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.	TPMT	mercaptopurine	22019	1994	0	0
DPWG	PA166104960	Select an alternative drug or reduce the initial dose of thioguanine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.	TPMT	thioguanine	22019	3233	0	0
DPWG	PA166265341	Avoid lamotrigine in patients with HLA-B*1502 if an alternative is available. If avoidance is not possible, advise to report any rash immediately.	HLA-B	lamotrigine	8015	1789	0	0
RNPGx	PA166202481	Testing for the CYP3A5*3 and CYP3A4*22 alleles is recommended in patients receiving a kidney, heart or lung transplant. CYP3A extensive or intermediate meatbolizers (EMs or IMs) should be given an initial dose of tacrolimus 1.5-2 times higher than that recommended for CYP3A poor metabolizers (PMs), up to a maximum dose of 0.30 mg/kg/day.	CYP3A4	tacrolimus	4366	3127	0	0
RNPGx	PA166202481	Testing for the CYP3A5*3 and CYP3A4*22 alleles is recommended in patients receiving a kidney, heart or lung transplant. CYP3A extensive or intermediate meatbolizers (EMs or IMs) should be given an initial dose of tacrolimus 1.5-2 times higher than that recommended for CYP3A poor metabolizers (PMs), up to a maximum dose of 0.30 mg/kg/day.	CYP3A5	tacrolimus	4368	3127	0	0
CPIC	PA166127639	The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor sertraline recommends to consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 poor metabolizers.	CYP2C19	sertraline	4349	2963	0	0
CPIC	PA166104997	In individuals with the HLA-B*57:01 variant allele ("HLA-B*57:01-positive"), abacavir is not recommended and should be considered only under exceptional circumstances. See full guideline for disclaimers, further details and supporting evidence.	HLA-B	abacavir	8015	26	0	0
CPNDS	PA166170752	The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of pharmacogenetic testing for variants in VKORC1 and CYP2C9 in adult and pediatric patients with an indication for warfarin. They recommend testing for the VKORC1 SNP -1639G>A (rs9923231) and the CYP2C9 alleles *2 and *3 in order to better guide warfarin dosage.	CYP2C9	warfarin	4351	3480	0	0
DPWG	PA166211021	The Dutch Pharmacogenetics Working Group Guideline for siponimod recommends decreasing the dose for CYP2C9 *1/*3, *2/*3 genotypes and to avoid siponimod for the CYP2C9 *3/*3 genotype.	CYP2C9	siponimod	4351	2982	0	0
CPIC	PA166192321	The CPIC Dosing Guideline for piroxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.	CYP2C9	piroxicam	4351	2638	0	0
CPIC	PA166228121	CYP2D6 intermediate and poor metabolizers should initiate hydrocodone therapy using the label recommended age- or weight-specific dosing. However, if there is no response to hydrocodone in these patients, an alternative analgesic should be considered.	CYP2D6	hydrocodone	4352	1589	0	0
CPIC	PA166228101	Alternate non-codeine analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific dose of tramadol is warranted for CYP2D6 normal and intermediate metabolizers.	CYP2D6	tramadol	4352	3302	0	0
DPWG	PA166104988	The recommendation for CYP2D6 poor metabolizers is to use 60% of the standard dose of haloperidol and for CYP2D6 ultrarapid metabolizers to use 1.5 times the standard dose or to choose an alternative to haloperidol.	CYP2D6	haloperidol	4352	1542	0	0
CPIC	PA166104945	Consider an alternate agent or extreme dose reduction of mercaptopurine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	NUDT15	mercaptopurine	13756	1994	0	0
CPIC	PA166104945	Consider an alternate agent or extreme dose reduction of mercaptopurine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	TPMT	mercaptopurine	22019	1994	0	0
DPWG	PA166104939	An alternative drug to fluorouracil is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for fluorouracil, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as "essential" and recommend DPYD testing prior to initiating fluoropyrimidines.	DPYD	fluorouracil	5039	1390	0	0
DPWG	PA166264881	Phenytoin should be avoided if possible in patients with the HLA-B*15:02 allele.	HLA-B	phenytoin	8015	2604	0	0
DPWG	PA166265421	Patients who are CYP3A4 poor metabolizers and being treated for depression should be given an alternative drug. Patients being treated for other indications and who are CYP3A4 poor metabolizers should be given a reduced dose of quetiapine. No action is needed for patients who are CYP3A4 intermediate metabolizers.	CYP3A4	quetiapine	4366	2788	0	0
CPIC	PA166219103	The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.	CYP2C19	lansoprazole	4349	1790	0	0
CPIC	PA166219103	The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.	CYP2C19	omeprazole	4349	2271	0	0
CPIC	PA166219103	The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.	CYP2C19	pantoprazole	4349	2503	0	0
CPIC	PA166119846	Rasburicase is contraindicated in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a negative or inconclusive genetic test result an enzyme activity test is recommended prior to rasburicase treatment to determine whether a patient is G6PD deficient. The G6PD gene is X-linked and therefore males only have one copy, whereas females have two copies. See full guideline for disclaimers, further details and supporting evidence.	G6PD	rasburicase	6821	2819	1	0
DPWG	PA166265162	Consider an alternative drug to carbamazepine in patients with the HLA-B*1502 0r HLA-B*1511 alleles.	HLA-B	carbamazepine	8015	665	0	0
CPIC	PA166262341	CYP2C9 IMs should avoid fluvastatin doses greater than 40mg while CYP2C9 PMs should avoid doses greater than 20mg.  If higher doses are required for desired efficacy, an alternative statin should be considered. Patients with SLCO1B1 poor function should also avoid fluvastatin doses greater than 40mg and and adjust doses of fluvastatin based on disease-specific guidelines. Patients with both SLCO1B1 poor function and CYP2C9 IM/PM should be prescribed an alternative statin depending on the desired potency.	CYP2C9	fluvastatin	4351	1406	1	1
CPIC	PA166262341	CYP2C9 IMs should avoid fluvastatin doses greater than 40mg while CYP2C9 PMs should avoid doses greater than 20mg.  If higher doses are required for desired efficacy, an alternative statin should be considered. Patients with SLCO1B1 poor function should also avoid fluvastatin doses greater than 40mg and and adjust doses of fluvastatin based on disease-specific guidelines. Patients with both SLCO1B1 poor function and CYP2C9 IM/PM should be prescribed an alternative statin depending on the desired potency.	SLCO1B1	fluvastatin	19487	1406	1	1
CPIC	PA166180457	The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.	CACNA1S	desflurane	2292	1004	0	0
CPIC	PA166180457	The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.	RYR1	desflurane	18364	1004	0	0
CPIC	PA166180457	The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.	CACNA1S	enflurane	2292	1220	0	0
CPIC	PA166180457	The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.	RYR1	enflurane	18364	1220	0	0
CPIC	PA166180457	The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.	CACNA1S	halothane	2292	1544	0	0
CPIC	PA166180457	The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.	RYR1	halothane	18364	1544	0	0
CPIC	PA166180457	The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.	CACNA1S	isoflurane	2292	1740	0	0
CPIC	PA166180457	The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.	RYR1	isoflurane	18364	1740	0	0
CPIC	PA166180457	The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.	CACNA1S	methoxyflurane	2292	2026	0	0
CPIC	PA166180457	The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.	RYR1	methoxyflurane	18364	2026	0	0
CPIC	PA166180457	The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.	CACNA1S	sevoflurane	2292	2966	0	0
CPIC	PA166180457	The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.	RYR1	sevoflurane	18364	2966	0	0
CPIC	PA166180457	The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.	CACNA1S	succinylcholine	2292	3060	0	0
CPIC	PA166180457	The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.	RYR1	succinylcholine	18364	3060	0	0
CPIC	PA166104999	Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including imipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.	CYP2C19	imipramine	4349	1648	0	0
CPIC	PA166104999	Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including imipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.	CYP2D6	imipramine	4352	1648	0	0
CPIC	PA166176068	The CPIC Dosing Guideline for tamoxifen recommends the use of alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women for CYP2D6 poor metabolizer, if aromatase inhibitor use is not contraindicated. For CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an activity score (AS) of 1 the recommendation is to consider the recommendations stated for the CYP2D6 poor metabolizer. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose for CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an AS of 1. For poor metabolizer, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy.	CYP2D6	tamoxifen	4352	3137	0	0
CPIC	PA166182603	Consider initiating efavirenz with a decreased dose of either 400 or 200 mg/day for patients who are CYP2B6 poor metabolizers. Consider initiating efavirenz with a decreased dose of 400 mg/day for patients who are CYP2B6 intermediate metabolizers.	CYP2B6	efavirenz	4346	1186	0	0
RNPGx	PA166202501	Testing for the main CYP2C19 deficiency alleles before instituting clopidogrel treatment is recommended (a test is essential for coronary angioplasty with stenting and based on the current state of knowledge this test is potentially useful in the other indications). For patients carrying at least one deficiency allele, the RNPGx recommends using an alternative treatment that is not a CYP2C19 substrate (eg. prasugrel, ticagrelor).	CYP2C19	clopidogrel	4349	842	0	0
CPIC	PA166122806	Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele ("HLA-B*15:02-positive") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin.	CYP2C9	fosphenytoin	4351	1430	0	0
CPIC	PA166122806	Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele ("HLA-B*15:02-positive") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin.	HLA-B	fosphenytoin	8015	1430	0	0
CPIC	PA166122806	Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele ("HLA-B*15:02-positive") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin.	CYP2C9	phenytoin	4351	2604	0	0
CPIC	PA166122806	Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele ("HLA-B*15:02-positive") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin.	HLA-B	phenytoin	8015	2604	0	0
CPIC	PA166262241	Prescribe an alternative statin depending on the desired potency for patients with SLCO1B1 decreased function, possible decreased function or poor function phenotype. If lovastatin therapy is warranted in patients with SLCO1B1 decreased or possible decreased phenotype, limit dose to <20mg/day.	SLCO1B1	lovastatin	19487	1894	0	1
CPNDS	PA166170751	The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of pharmacogenetic testing for TPMT gene variants when prescribing cisplatin in pediatric cancer patients. They recommend testing for the TPMT alleles *2, *3A, *3B or *3C in all pediatric cancer patients due to the association of these alleles with an increased risk of cisplatin-induced ototoxicity.	TPMT	cisplatin	22019	818	0	0
CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	MT-RNR1	amikacin	12748	173	1	0
CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	MT-RNR1	gentamicin	12748	1476	1	0
CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	MT-RNR1	kanamycin	12748	1768	1	0
CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	MT-RNR1	paromomycin	12748	2519	1	0
CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	MT-RNR1	plazomicin	12748	2651	1	0
CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	MT-RNR1	streptomycin	12748	3052	1	0
CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	MT-RNR1	tobramycin	12748	3278	1	0
DPWG	PA166104957	For CYP2C19 ultrarapid metabolizers who are undergoing H. pylori eradication therapy, use a 3-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 3-fold higher dose.	CYP2C19	omeprazole	4349	2271	0	0
DPWG	PA166265141	Individuals with the HLA-B*58:01 allele should be given an alternative drug or undergo induction of allopurinol tolerance.	HLA-B	allopurinol	8015	127	0	0
AusNZ	PA166257241	An alternative antifungal agent should be considered instead of voriconazole in patients who are known to be CYP2C19 ultrarapid metabolizers. CYP2C19 genotyping and use of an alternative antifungal agent is also recommended in patients with subtherapeutic voriconazole serum concentrations despite two dose adjustments.	CYP2C19	voriconazole	4349	3473	0	0
DPWG	PA166104987	For CYP2C19 ultrarapid metabolizers who are undergoing H. pylori eradication therapy, use a 4-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 4-fold higher dose.	CYP2C19	lansoprazole	4349	1790	0	1
DPWG	PA166265201	Oxcarbazepine should be avoided if an alternative is available in patients with the HLA-B*15:02 allele.	HLA-B	oxcarbazepine	8015	2468	0	0
RNPGx	PA166202781	The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) states that methotrexate pharmacogenetic tests are potentially useful in cancer patients.	ABCB1	methotrexate	48	2022	0	0
RNPGx	PA166202781	The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) states that methotrexate pharmacogenetic tests are potentially useful in cancer patients.	MTHFR	methotrexate	12708	2022	0	0
RNPGx	PA166202781	The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) states that methotrexate pharmacogenetic tests are potentially useful in cancer patients.	SLC19A1	methotrexate	19146	2022	0	0
RNPGx	PA166202781	The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) states that methotrexate pharmacogenetic tests are potentially useful in cancer patients.	SLCO1B1	methotrexate	19487	2022	0	0
CPIC	PA166105006	The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.	CYP2C19	amitriptyline	4349	195	0	0
CPIC	PA166105006	The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.	CYP2D6	amitriptyline	4352	195	0	0
DPWG	PA166104955	In individuals who carry the Factor V Leiden allele (rs6025 T) and have a family history of thrombotic events, estrogen-containing oral contraceptives should be avoided and alternative forms of contraception used.	F5	hormonal contraceptives for systemic use	5820	1576	0	0
DPWG	PA166182842	Reduce warfarin dose in CYP2C9 poor and intermediate metabolizers (PM and IM) and patients with CYP2C9*1/*3, *2/*3, *2/*2 or *3/*3 genotype. "The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see Algorithms coumarins"	CYP2C9	warfarin	4351	3480	0	0
CPIC	PA166105008	The CPIC Dosing Guideline update for carbamazepine recommends an alternative drug for carbamazepine-naive patients carrying at least one copy of either HLA-B*15:02 or HLA-A*31:01 due to the association of those alleles with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). In addition, HLA-A*31:01 is associated with an increased risk of drug reaction with eosinophilia and systemic symptoms (DRESS) and maculopapular exanthema (MPE).	HLA-A	carbamazepine	8014	665	0	0
CPIC	PA166105008	The CPIC Dosing Guideline update for carbamazepine recommends an alternative drug for carbamazepine-naive patients carrying at least one copy of either HLA-B*15:02 or HLA-A*31:01 due to the association of those alleles with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). In addition, HLA-A*31:01 is associated with an increased risk of drug reaction with eosinophilia and systemic symptoms (DRESS) and maculopapular exanthema (MPE).	HLA-B	carbamazepine	8015	665	0	0
DPWG	PA166104982	The Dutch Pharmacogenetics Working Group Guideline for amitriptyline recommends decreasing the dose for CYP2D6 intermediate and CYP2D6 poor metabolizers and increasing the dose or using an alternative drug for CYP2D6 ultra-rapid metabolizers.	CYP2D6	amitriptyline	4352	195	0	0
ACR	PA166104993	Testing for the HLA-B*58:01 allele before starting allopurinol treatment is conditionally recommended for patients of Southeast Asian or African American descent.	HLA-B	allopurinol	8015	127	0	0
DPWG	PA166104992	For CYP2D6 poor and intermediate metabolizers, reduce zuclopenthixol dose or select an alternative drug that is not metabolized by CYP2D6. For ultrarapid metabolizers, be alert to low zuclopenthixol plasma concentrations and, if necessary, increase the dose or select an alternative drug.	CYP2D6	zuclopenthixol	4352	3528	0	0
CPIC	PA166127637	The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor fluvoxamine recommends to consider a 25-50% reduction of recommended starting dose and titrate to response or use an alternative drug not metabolized by CYP2D6 for CYP2D6 poor metabolizers.	CYP2D6	fluvoxamine	4352	1407	0	0
CPIC	PA166105005	Prescribe an alternative statin depending on the desired potency for patients with SLCO1B1 decreased function, possible decreased function or poor function phenotype. If simvastatin therapy is warranted in patients with SLCO1B1 decreased or possible decreased phenotype, limit dose to <20mg/day.	SLCO1B1	simvastatin	19487	2979	1	1
DPWG	PA166104977	The Dutch Pharmacogenetics Working Group Guideline for citalopram recommends for intermediate and poor metabolizers of CYP2C19 to not exceed the in the DPWG document specified daily doses.	CYP2C19	citalopram	4349	819	0	0
DPWG	PA166104951	Dose reductions are recommended for irinotecan for patients who are UGT1A1 *28/*28 or UGT1A1 PM, starting with 70% of starting dose and increasing as tolerated, guided by neutrophil count.	UGT1A1	irinotecan	22969	1725	0	0
DPWG	PA166104990	Patients who are CYP2C19 poor metabolizers should receive 50% of the standard dose, and CYP2C19 ultrarapid metabolizers should receive a 1.5 times higher initial dose. Monitor voriconazole plasma concentrations for CYP2C19 poor, intermediate and ultrarapid metabolizers.	CYP2C19	voriconazole	4349	3473	0	0
DPWG	PA166104994	The Dutch Pharmacogenetics Working Group Guideline for doxepin recommends dose changes and to monitor the effect and side effects or the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), intermediate (IM), and ultrarapid (UM) metabolizer or to avoid doxepin in UM.	CYP2D6	doxepin	4352	1126	0	0
DPWG	PA166104968	For CYP2D6 poor (PM) and intermediate metabolizers (IM), select an alternative to venlafaxine or reduce the dose and monitor patient's plasma metabolite level. For CYP2D6 ultrarapid metabolizers (UM), increase dose to 150% of the normal dose or select an alternative to venlafaxine.	CYP2D6	venlafaxine	4352	3423	0	0
DPWG	PA166104980	Do not give doses exceeding 75 mg/day in patients with CYP2C19 poor metabolizer genotypes, and guide the dose by response and side effects and/or sertraline plasma concentration.	CYP2C19	sertraline	4349	2963	0	0
CPIC	PA166191841	The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.	CYP2C9	celecoxib	4351	736	0	0
CPIC	PA166191841	The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.	CYP2C9	flurbiprofen	4351	1400	0	0
CPIC	PA166191841	The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.	CYP2C9	ibuprofen	4351	1621	0	0
CPIC	PA166191841	The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.	CYP2C9	lornoxicam	4351	1890	0	0
DPWG	PA166104959	Be alert to a reduced efficacy of tramadol in CYP2D6 intermediate or poor metabolizers. If tramadol is not effective in these patients, try a dose increase or select an alternative to tramadol (not codeine) and be alert for symptoms of insufficient pain relief. For CYP2D6 ultrarapid metabolizers, use an alternative to tramadol (not codeine) or use 40% of the standard dose and be alert to side effects.	CYP2D6	tramadol	4352	3302	0	0
DPWG	PA166104976	Select an alternative drug rather than paroxetine for CYP2D6 ultrarapid metabolizer patients.	CYP2D6	paroxetine	4352	2520	0	0
DPWG	PA166104983	Increased doses of tacrolimus are recommended for CYP3A5 heterozygous and homozygous expressors and adjusted as needed. Instructions for liver transplantation patients include genotypes of both patient and donor.	CYP3A5	tacrolimus	4368	3127	0	0
DPWG	PA166104961	The Dutch Pharmacogenetics Working Group Guideline for nortriptyline recommends a dose reduction for CYP2D6 poor or intermediate metabolizer patients. For CYP2D6 ultrarapid metabolizers, select an alternative drug or use 1.7 times the standard dose. Monitoring of nortriptyline and 10-hydroxynortriptyline plasma concentrations is recommended.	CYP2D6	nortriptyline	4352	2240	0	0
DPWG	PA166182823	The Dutch Pharmacogenetics Working Group Guideline for eliglustat recommends to use an alternative in CYP2D6 ultrarapid metabolizer. For CYP2D6 poor metabolizer in combination with CYP3A inhibitors and strong inducers, the guideline recommends to choose an alternative if possible. For intermediate metabolizers recommendations are provided for co-medication with CYP2D6 and/or CYP3A inhibitors and CYP3A inducers.	CYP2D6	eliglustat	4352	1202	0	0
CPIC	PA166104933	Consider an alternate agent or extreme dose reduction of azathioprine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	NUDT15	azathioprine	13756	432	0	0
CPIC	PA166104933	Consider an alternate agent or extreme dose reduction of azathioprine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	TPMT	azathioprine	22019	432	0	0
DPWG	PA166104934	Select an alternative drug or reduce the initial dose of azathioprine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.	TPMT	azathioprine	22019	432	0	0
CPIC	PA166110235	IFNL3 (IL28B) variation (rs12979860) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients.  Patients with the favorable response genotype (rs12979860 CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (rs12979860 CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.	IFNL3	peginterferon alfa-2a	8531	2529	0	0
CPIC	PA166110235	IFNL3 (IL28B) variation (rs12979860) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients.  Patients with the favorable response genotype (rs12979860 CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (rs12979860 CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.	IFNL3	peginterferon alfa-2b	8531	2530	0	0
CPIC	PA166110235	IFNL3 (IL28B) variation (rs12979860) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients.  Patients with the favorable response genotype (rs12979860 CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (rs12979860 CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.	IFNL3	ribavirin	8531	2851	0	0
CPNDS	PA166181721	The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published clinical practice guidelines for CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients. The guidelines recommend that alternatives to standard tamoxifen treatments may be considered in CYP2D6 poor or intermediate metabolizers with an emphasis on the use of comprehensive CYP2D6 genotyping panels in guiding treatment decisions.	CYP2D6	tamoxifen	4352	3137	0	0
CPIC	PA166109594	The CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50%. Patients with the c.[2846A>T];[2846A>T] genotype may require a >50% dose reduction.	DPYD	capecitabine	5039	655	0	0
DPWG	PA166264961	Patients with the GT or TT genotypes at rs2231142 should be given an increased dose of allopurinol.	ABCG2	allopurinol	83	127	0	0
CPIC	PA166104965	Consider an alternate agent or extreme dose reduction of thioguanine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 50-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	NUDT15	thioguanine	13756	3233	0	0
CPIC	PA166104965	Consider an alternate agent or extreme dose reduction of thioguanine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 50-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	TPMT	thioguanine	22019	3233	0	0
DPWG	PA166265161	Consider an alternative drug to carbamazepine in patients with the HLA-A*3101 allele.	HLA-A	carbamazepine	8014	665	0	0
RNPGx	PA166202761	The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends testing for TPMT.	TPMT	mercaptopurine	22019	1994	0	0
DPWG	PA166104943	The Dutch Pharmacogenetics Working Group Guideline for risperidone recommends decreasing the dose for CYP2D6 poor metabolizers and using an alternative drug or titrate the dose according to the maximum dose for the active metabolite for CYP2D6 ultrarapid metabolizers.	CYP2D6	risperidone	4352	2871	0	0
CPIC	PA166104998	The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers.	CYP2D6	nortriptyline	4352	2240	0	0
CPIC	PA166104948	The CPIC Dosing Guideline for clopidogrel recommends an alternative antiplatelet therapy for CYP2C19 poor or intermediate metabolizers (cardiovascular indications: prasugrel or ticagrelor if no contraindication; neurovascular indications: alternative P2Y12 inhibitor if clinically indicated and no contraindication.)	CYP2C19	clopidogrel	4349	842	0	0
CPNDS	PA166117280	The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of HLA-A*31:01 or HLA-B*15:02 genotype when prescribing carbamazepine (CBZ).  They recommend that carbamazepine not be prescribed for CBZ-naive patients who carry at least one HLA-A*31:01 or HLA-B*15:02 allele.	HLA-A	carbamazepine	8014	665	0	0
CPNDS	PA166117280	The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of HLA-A*31:01 or HLA-B*15:02 genotype when prescribing carbamazepine (CBZ).  They recommend that carbamazepine not be prescribed for CBZ-naive patients who carry at least one HLA-A*31:01 or HLA-B*15:02 allele.	HLA-B	carbamazepine	8015	665	0	0
DPWG	PA166104958	For CYP2C19 ultrarapid metabolizers who are undergoing H. pylori eradication therapy, use a 5-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 5-fold higher dose.	CYP2C19	pantoprazole	4349	2503	0	0
DPWG	PA166104966	For CYP2D6 poor and intermediate metabolizers, consider an alternative medication or a dose increase. For intermediate metabolizers, avoid concomitant CYP2D6 inhibitor use.	CYP2D6	tamoxifen	4352	3137	0	0
DPWG	PA166182846	Adjust the initial efavirenz dose for patients with the CYP2B6 PM phenotype along with the consideration of age, weight and BMI and titrate the dose to plasma concentration if needed. For patients with the *5/*6, *5/*18 or other CYP2B6 IM genotypes, determine the efavirenz plasma concentration if side effects occur and reduce the dose if needed.	CYP2B6	efavirenz	4346	1186	0	0
CPIC	PA166181885	The CPIC Dosing Guideline for atomoxetine provides therapeutic recommendations for CYP2D6 ultrarapid, normal, intermediate, and poor metabolizer, which includes guidance for plasma drug concentration testing, as a means to estimate atomoxetine exposure, if no clinical response and in the absence of adverse events after 2 weeks of therapy.	CYP2D6	atomoxetine	4352	413	0	0
CPIC	PA166192301	The CPIC Dosing Guideline for meloxicam recommends alternative therapy for CYP2C9 poor metabolizers due to markedly prolonged half-life, and initiating therapy with 50% of the lowest recommended starting dose or choose an alternative therapy for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.	CYP2C9	meloxicam	4351	1977	0	0
CPIC	PA166161537	The CPIC dosing guideline for voriconazole recommends selecting an alternative agent that is not dependent on CYP2C19 metabolism in adults who are CYP2C19 ultrarapid metabolizers, rapid metabolizers or poor metabolizers. In pediatric patients, an alternative agent should be used in patients who are ultrarapid metabolizers or poor metabolizers. In pediatric rapid metabolizers, therapy should be initiated at recommended standard case dosing, then therapeutic dosing monitoring should be used to titrate dose to therapeutic trough concentrations.	CYP2C19	voriconazole	4349	3473	0	0
DPWG	PA166182810	Monitor for liver function and select an alternative drug instead of flucloxacillin if liver enzymes or bilirubin is elevated, for patients that are HLA-B*5701.	HLA-B	flucloxacillin	8015	1371	0	0
CPIC	PA166262261	Prescribe ≤1mg as a starting dose for patients with SLCO1B1 poor function phenotype. Prescribe ≤2mg as a starting dose for patients with SLCO1B1 decreased or possible decreased phenotype. Adjust doses of pitavastatin based on disease-specific guidelines. Consider an alternative statin or combination therapy if higher doses are needed.	SLCO1B1	pitavastatin	19487	2639	0	1
CPIC	PA166127636	The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor paroxetine recommends an alternative drug not predominantly metabolized by CYP2D6 for CYP2D6 ultrarapid metabolizers and for CYP2D6 poor metabolizers. For CYP2D6 poor metabolizers, if paroxetine use is warranted, consider a 50% reduction of recommended starting dose and titrate to response.	CYP2D6	paroxetine	4352	2520	0	0
DPWG	PA166104969	Reduce flecainide dose by 50% for CYP2D6 poor metabolizer (PM) and record an ECG and monitor the plasma concentration. Reduce flecainide dose to 75% of the standard dose for CYP2D6 intermediate metabolizer (IM) patients with indications other than diagnosis of Brugada syndrome and record an ECG and monitor the plasma concentration.	CYP2D6	flecainide	4352	1368	0	0
DPWG	PA166104975	The Dutch Pharmacogenetics Working Group Guideline for escitalopram recommends for intermediate and poor metabolizers of CYP2C19 to not exceed the in the DPWG document specified doses and for CYP2C19 ultrarapid metabolizer to avoid escitalopram.	CYP2C19	escitalopram	4349	1263	0	0
DPWG	PA166182843	Choose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, advise the patients to contact their doctor in the event of muscle symptoms.	SLCO1B1	atorvastatin	19487	414	0	0
CPIC	PA166124619	The CPIC dosing guideline for tacrolimus recommends increasing the starting dose by 1.5 to 2 times the recommended starting dose in patients who are CYP3A5 intermediate or extensive metabolizers, though total starting dose should not exceed 0.3 mg/kg/day. Therapeutic drug monitoring should also be used to guide dose adjustments.	CYP3A5	tacrolimus	4368	3127	0	0
DPWG	PA166184614	Select an alternative drug or reduce the initial dose of azathioprine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.	NUDT15	azathioprine	13756	432	0	0
DPWG	PA166184612	Select an alternative drug or reduce the initial dose of thioguanine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.	NUDT15	thioguanine	13756	3233	0	0
RNPGx	PA166127626	A French joint working group comprising the National Pharmacogenetics Network (RNPGx) and the Group of Clinical Onco-pharmacology (GPCO-Unicancer) has published guidelines for the use of UGT1A1*28 genotype when prescribing irinotecan. They recommend that the dose of irinotecan be reduced in patients with the UGT1A1*28/*28 genotype, and that high-dose irinotecan (>=240 mg/m2) only be prescribed to patients with the UGT1A1*1/*1 genotype. The French National Network of Pharmacogenetics (RNPGx) included recommendations for irinotecan in  a 2017 paper on several anti-cancer drugs.	UGT1A1	irinotecan	22969	1725	0	0
DPWG	PA166184528	The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to avoid clomipramine in CYP2C19 ultrarapid metabolizer (UM) for Indication OBSESSIVE COMPULSIVE DISORDER or ANXIETY DISORDERS.	CYP2C19	clomipramine	4349	838	0	0
CPIC	PA166219301	The CPIC Dosing Guideline recommendations for dexlansoprazole are based on the similarity in its metabolism and lansoprazole and extrapolated from the first-generation PPIs. The guideline recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizers for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.	CYP2C19	dexlansoprazole	4349	1023	0	0
CPIC	PA166161954	The CPIC dosing guideline for ondansetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron).	CYP2D6	ondansetron	4352	2273	0	0
RNPGx	PA166202621	Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.	CYP2C9	acenocoumarol	4351	44	0	0
RNPGx	PA166202621	Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.	VKORC1	acenocoumarol	23312	44	0	0
RNPGx	PA166202621	Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.	CYP2C9	fluindione	4351	1378	0	0
RNPGx	PA166202621	Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.	VKORC1	fluindione	23312	1378	0	0
RNPGx	PA166202621	Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.	CYP2C9	warfarin	4351	3480	0	0
RNPGx	PA166202621	Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.	VKORC1	warfarin	23312	3480	0	0
CPIC	PA166105007	Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including clomipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.	CYP2C19	clomipramine	4349	838	0	0
CPIC	PA166105007	Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including clomipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.	CYP2D6	clomipramine	4352	838	0	0
DPWG	PA166104963	An alternative drug to capecitabine is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for capecitabine, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as "essential" and recommend DPYD testing prior to initiating fluoropyrimidines.	DPYD	capecitabine	5039	655	0	0
RNPGx	PA166202561	Testing for rs4149056 before starting statin treatment, or early after treatment onset (potentially useful test) is recommended in patients with one or more risk factors described (as a function of statin type and dose, co-medications, and the pathophysiological or genetic setting). If the genotype is not known early, the RNPGx considers that a polymorphism test is potentially useful in the event of muscle toxicity in patients treated with statins, in order to rule out or confirm a genetic cause.	SLCO1B1	hmg coa reductase inhibitors	19487	1571	0	0
RNPGx	PA166202561	Testing for rs4149056 before starting statin treatment, or early after treatment onset (potentially useful test) is recommended in patients with one or more risk factors described (as a function of statin type and dose, co-medications, and the pathophysiological or genetic setting). If the genotype is not known early, the RNPGx considers that a polymorphism test is potentially useful in the event of muscle toxicity in patients treated with statins, in order to rule out or confirm a genetic cause.	SLCO1B1	simvastatin	19487	2979	0	0
CPIC	PA166128738	The CPIC dosing guideline recommends considering advising individuals who carry two decreased function UGT1A1 alleles about a substantial likelihood of developing jaundice, which may cause non-adherence. The dosing guideline recommends that alternative agents be considered if the risk of non-adherence due to jaundice is high. The risk of discontinuation is low and very low for individuals carrying one, or no decreased function UGT1A1 alleles, respectively.	UGT1A1	atazanavir	22969	408	0	0
DPWG	PA166104956	Avoid clopidogrel use in patients who are CYP2C19 poor metabolizers and are undergoing percutaneous coronary intervention, stroke or TIA. For CYP2C19 intermediate metabolizers who are undergoing percutaneous coronary intervention, stroke, or TIA, choose an alternative drug or double the dose to 150 mg/day (600 mg loading dose). No action is required for patients who are CYP2C19 ultra-rapid metabolizers.	CYP2C19	clopidogrel	4349	842	0	0
CPIC	PA166161955	The CPIC dosing guideline for tropisetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron).	CYP2D6	tropisetron	4352	3349	0	0
DPWG	PA166104954	CYP2C19 poor metabolizers should receive 70% of the standard dose of imipramine, or imipramine should be avoided in these patients. Patients should be monitored for the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose.	CYP2C19	imipramine	4349	1648	0	0
CPIC	PA166192341	The CPIC Dosing Guideline for tenoxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.	CYP2C9	tenoxicam	4351	3177	0	0
CPIC	PA166262281	Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines for patients with SLCO1B1 poor function phenotype. Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines for patients with SLCO1B1 decreased or possible decreased phenotype. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.	SLCO1B1	pravastatin	19487	2688	0	1
RNPGx	PA166202721	The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends testing for DPYD deficiency before initiating a treatment regimen based on 5-FU or capecitabine, with dose reductions for DPYD partial deficiency and contraindicates fluoropyrimidines in patients with complete deficiency.	DPYD	capecitabine	5039	655	0	0
RNPGx	PA166202721	The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends testing for DPYD deficiency before initiating a treatment regimen based on 5-FU or capecitabine, with dose reductions for DPYD partial deficiency and contraindicates fluoropyrimidines in patients with complete deficiency.	DPYD	fluorouracil	5039	1390	0	0
DPWG	PA166104995	For CYP2D6 poor and intermediate metabolizer patients, if a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA, use smaller steps in dose titration and/or prescribe no more than 25% or 50% of the standard dose, respectively. For CYP2D6 ultra metabolizers, use the maximum dose for the relevant indication as a target dose, and if the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative drug.	CYP2D6	metoprolol	4352	2052	0	0
DPWG	PA166104984	Use the standard starting dose of phenytoin and reduce the maintenance dose based on CYP2C9 genotype; monitor response and serum concentrations and be aware of ADEs.	CYP2C9	phenytoin	4351	2604	0	0
CPNDS	PA166122666	The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of CYP2D6 genotype when prescribing codeine. They recommend that poor metabolizers of CYP2D6 should not receive codeine for pain relief, and ultrametabolizers of CYP2D6 should avoid codeine for pain relief.	CYP2D6	codeine	4352	854	0	0
DPWG	PA166104937	The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends reducing maximum dose of aripiprazole for patients carrying poor metabolizer alleles of CYP2D6.	CYP2D6	aripiprazole	4352	380	0	0
RNPGx	PA166202701	The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends CYP2D6 and CYP2C19 genotyping before initiating an antidepressant treatment, especially in patients with a high risk of toxicity.	CYP2C19	antidepressants	4349	280	0	0
RNPGx	PA166202701	The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends CYP2D6 and CYP2C19 genotyping before initiating an antidepressant treatment, especially in patients with a high risk of toxicity.	CYP2D6	antidepressants	4352	280	0	0
DPWG	PA166184527	The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to use half of the standard dose of brexpiprazole for patients carrying poor metabolizer alleles of CYP2D6.	CYP2D6	brexpiprazole	4352	578	0	0
CPIC	PA166262221	Prescribe ≤20mg for patients with SLCO1B1 poor function phenotype and ≤40mg for patients with SLCO1B1 decreased or possible decreased phenotype as a starting dose.  Adjust doses of atorvastatin based on disease-specific guidelines.  Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose.	SLCO1B1	atorvastatin	19487	414	0	1
CFF	PA166178241	Ivacaftor is suggested for some cystic fibrosis patients with specific CFTR gating mutations, including the R117H or G551D variants.	CFTR	ivacaftor	3250	1759	0	0
